Is this you? As a journalist, you can create a free Muck Rack account to customize your profile, list your contact preferences, and upload a portfolio of your best work.
Claim your profile
Get in touch with Diying
Contact Diying, search articles and posts on X, monitor coverage, and track replies from one place.
Learn more about Muck RackActions
Is this you?
As a journalist, you can create a free Muck Rack account to customize your profile, list your contact preferences, and upload a portfolio of your best work.Articles
Measurable residual disease detected by next-generation sequencing in T-cell acute lymphoblastic leukemia
Abstract The clinical utility of measurable residual disease monitoring based on next-generation sequencing in T-cell acute lymphoblastic leukemia remains incompletely defined. Here we show the prognostic value of tracking clonal T-cell receptor gene rearrangements by next-generation sequencing in pediatric patients with T-cell acute lymphoblastic leukemia.
In recent years, the targeted therapy combining arsenic with all-trans retinoic acid (ATRA) has dramatically improved outcomes in pediatric acute promyelocytic leukemia (APL) [1, 2]. However, 5–10% of patients still experience relapse [3], which remains a major barrier to cure. Within this modern therapeutic framework, the risk factors for relapse in pediatric APL—particularly the role of arsenic pharmacokinetics—are not fully defined.
Actions
Is this you?
As a journalist, you can create a free Muck Rack account to customize your profile, list your contact preferences, and upload a portfolio of your best work.Get in touch with Diying
Contact Diying, search articles and posts on X, monitor coverage, and track replies from one place.
Learn more about Muck Rack